Drew Vonderahe
I help drive the expansion of LCP’s Patient Services and Access Solutions consulting practice, supporting biopharmaceutical clients in achieving rapid, broad, and sustainable patient access to innovative therapies.
With more than twenty years of experience spanning pharmaceutical market access, patient support operations, and process innovation, I bring deep expertise across patient services strategy, design, optimization, and implementation. I have led or advised on more than 50 specialty products across oncology, neurology, immunology, dermatology, and rare diseases—bridging clinical innovation with operational excellence.
Throughout my career, I have been instrumental in transforming patient services operations through the application of Lean Six Sigma and intelligent automation, helping clients build scalable, compliant, and data-driven service models. My consulting work has encompassed end-to-end PSP development—from journey mapping and partner selection to performance analytics and continuous improvement—ensuring measurable impact on access, affordability, and adherence.
Before joining LCP, I served as the founder and leader of Vocantem, leading US Market Access and Patient Services Consulting. Earlier in my career, I held leadership roles at UCB, BioIQ, and The Home Depot, where I developed a strong foundation in process design, change management, and global service excellence.
As a Six Sigma Black Belt and Georgia Tech MBA, I am passionate about advancing healthcare system performance by connecting patient-centered innovation with operational efficiency. My approach combines strategic insight, analytical rigor, and cross-functional collaboration to deliver tangible results for clients and patients alike.
Featured insights

Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.

Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.

Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.

Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.



